EU-103

• Description :

  EU-103 is a humanized monoclonal antibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a KD value ranging from 10−7 and 10−9. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer[1].

• UNSPSC :

  12352203

• Target :

  Transmembrane Glycoprotein

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Smiles :

  [EU-103]

• References & Citations :

  [1]Byoung S. Kwon, et al. Anti-human vsig4 antibodies and uses thereof. WO2020069507A1. 2020-04-02.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 1